ATRA
$5.23
Atara Biotherapeutics, Inc.
Recent News
Atara Biotherapeutics: Q4 Earnings Snapshot
ATRA) on Monday reported a loss of $3.4 million in its fourth quarter. The Thousand Oaks, California-based company said it had a loss of 25 cents per share. The drug developer posted revenue of $1.6 million in the period.
Pierre Fabre seeks to revive US approval chances for spurned cell therapy
Ebvallo is one of a series of rare disease treatments recently turned back by the FDA amid shifting guidance that has surprised some companies and frustrated investors.
Top Midday Decliners
Travere Therapeutics (TVTX) said the US Food and Drug Administration extended the review timeline of
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.
Atara Biotherapeutics: Q3 Earnings Snapshot
THOUSAND OAKS, Calif. AP) — Atara Biotherapeutics Inc. ATRA) on Wednesday reported a loss of $4.3 million in its third quarter.